

# **Global Periodontitis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets**

<https://marketpublishers.com/r/GC66DDCDDE7EN.html>

Date: August 2019

Pages: 55

Price: US\$ 1,799.00 (Single User License)

ID: GC66DDCDDE7EN

## **Abstracts**

High levels of pipeline activity are being observed in Periodontitis treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Cellatoz Therapeutics Inc, Cells for Cells SA, CSL Ltd, Geistlich Pharma AG, GlycoMira Therapeutics Inc and others.

A Significant contribution to the Periodontitis pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Periodontitis pipeline included 10 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Periodontitis condition and increased access to investments is encouraging growth of Periodontitis drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Periodontitis drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Periodontitis therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2,

phase 3 and pre-registration phases are also analyzed.

The current report examines the current Periodontitis pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Periodontitis. Further, orphan drug status, fast track designation, grants awarded and other special status for Periodontitis pipeline compounds are also included.

This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Periodontitis pipeline and formulate effective research and development strategies.

## **RESEARCH METHODOLOGY**

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

### Scope of the Research

#### Periodontitis Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Periodontitis drugs

Late phase: Phase 3 and in-approval Periodontitis drugs

#### Companies involved in the Pipeline-

Company overview

Snapshot

Periodontitis therapeutic treatment activities

Details for each Periodontitis drug candidate-

### Snapshot

Drug Name

Alternative Names

Company

Originator

Phase

Molecule Type

Orphan Drug Status

Drug Overview

Mechanism of Action

Current Status

Trial Details

### Other details

Pre-clinical trials for each drug candidate

Clinical trials for each drug candidate

Recent Periodontitis therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news

## Contents

### **1 TABLE OF CONTENTS**

- 1.1 List of Tables
- 1.2 List of Figures

### **2 EXECUTIVE SUMMARY**

- 2.1 Periodontitis- Disease Overview
- 2.2 Periodontitis- Pipeline Snapshot
- 2.3 Periodontitis- Pipeline Drugs by Phase
- 2.4 Periodontitis- Pipeline Drugs by Company
- 2.5 Periodontitis- Pipeline Drugs by Mechanism of Action

### **3 COMPANY WISE PIPELINE ANALYSIS**

- 3.1 Cellatoz Therapeutics Inc Periodontitis Drug Pipeline, H2- 2019
- 3.2 Cells for Cells SA Periodontitis Drug Pipeline, H2- 2019
- 3.3 CSL Ltd Periodontitis Drug Pipeline, H2- 2019
- 3.4 Geistlich Pharma AG Periodontitis Drug Pipeline, H2- 2019
- 3.5 GlycoMira Therapeutics Inc Periodontitis Drug Pipeline, H2- 2019
- 3.6 Guangzhou Saliat Stem cell Science and Technology Co Ltd Periodontitis Drug Pipeline, H2- 2019
- 3.7 KIMS Pharmaceutical Co Ltd Periodontitis Drug Pipeline, H2- 2019
- 3.8 Kuhnle Pharmaceutical Co Ltd Periodontitis Drug Pipeline, H2- 2019
- 3.9 Noveome Biotherapeutics Inc Periodontitis Drug Pipeline, H2- 2019
- 3.10 TGV Laboratories Inc Periodontitis Drug Pipeline, H2- 2019

### **4 PHASE 1 PIPELINE DRUG DETAILS**

- 4.1 Periodontitis- Phase 1 Drug Details
- 4.2 Periodontitis- Phase 1 Drug Overview
- 4.3 Periodontitis- Phase 1 Mechanism of Action
- 4.4 Current Status
- 4.5 Trial Details

### **5 PHASE 2 PIPELINE DRUG DETAILS**

- 5.1 Periodontitis- Phase 2 Drug Details
- 5.2 Periodontitis- Phase 2 Drug Overview
- 5.3 Periodontitis- Phase 2 Mechanism of Action
- 5.4 Current Status
- 5.5 Trial Details

## **6 PHASE 3 PIPELINE DRUG DETAILS**

- 6.1 Periodontitis- Phase 3 Drug Details
- 6.2 Periodontitis- Phase 3 Drug Overview
- 6.3 Periodontitis- Phase 3 Drug Mechanism of Action
- 6.4 Current Status
- 6.5 Trial Details

## **7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS**

- 7.1 Periodontitis- Pre-clinical Phase Drug Details
- 7.2 Periodontitis- Pre-clinical Phase Drug Overview
- 7.3 Periodontitis- Pre-clinical Phase Drug Mechanism of Action
- 7.4 Current Status
- 7.5 Trial Details

## **8 RECENT NEWS AND DEVELOPMENTS**

## **9 APPENDIX**

- 9.1 About VPAResearch
- 9.2 Sources and Research Methodology

## I would like to order

Product name: Global Periodontitis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

Product link: <https://marketpublishers.com/r/GC66DDCDDE7EN.html>

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC66DDCDDE7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

